Mullti Units France - Lyxor MSCI Europe (DR) UCITS ETF is a equity ETF from Amundi tracking the Mullti Units France - Lyxor MSCI Europe index through physical replication. Domiciled in Francia and launched in 2006, the fund manages about 608 M € and charges a TER of 0.25% — 25 € per year on a €10,000 investment. Income is automatically reinvested in the fund (accumulating).
Mullti Units France - Lyxor MSCI Europe (DR) UCITS ETF competes with 261 other products in the same class and region (Equity, Europe): it ranks 64th by fund size and 129th by ongoing cost, with a TER of 0.25% against a group median of 0.25%. It has been listed since 2006, 20 years of track record.
On a €10,000 investment the TER costs 25 € a year, against 25 € for the median product in the category.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 21.7% of the portfolio.
Income is accumulated: no distribution is paid out, the share price absorbs it. In a savings plan this removes the need to reinvest dividends by hand. The fund is denominated in EUR. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
The fund is domiciled in Francia, which determines the tax treatment of income received by the fund and the supervisory authority.
| ASML Holding N.V. | 5.4% |
| HSBC Holdings PLC | 2.3% |
| Roche Holding AG | 2.1% |
| Novartis AG | 2.0% |
| AstraZeneca PLC | 2.0% |
| Nestle S.A. | 1.9% |
| Siemens Aktiengesellschaft | 1.7% |
| Shell plc | 1.6% |
| Banco Santander S.A. | 1.4% |
| Allianz SE VNA O.N. | 1.3% |
| Borsa Italiana | MEU | EUR |
| XETRA | LYY5 | EUR |
| Francoforte | LYY5 | EUR |
| London Stock Exchange | MEUG | GBX |
| Euronext Paris | MEU | EUR |
| SIX Swiss Exchange | LYMEU | CHF |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.